In the landscape of pharmacovigilance (PV), aggregate safety reports are crucial tools for monitoring the benefit-risk profile of medicinal products. These reports help regulatory authorities assess the ongoing safety of drugs on the market or in clinical development. In the UK, as elsewhere, companies must submit different types of aggregate reports depending on the lifecycle stage of the product. This guide explores the four key types: PBRER, DSUR, PSUR, and PADER.
What Are Aggregate Reports?
Aggregate reports consolidate safety data over a defined period, summarising adverse events, benefit-risk evaluations, and new safety information. These documents provide a broader, cumulative perspective compared to single case reports and are essential for post-market surveillance and clinical trial oversight.
1. PBRER (Periodic Benefit-Risk Evaluation Report)
What It Is:
PBRER is a comprehensive document that evaluates the benefit-risk balance of a medicinal product after marketing authorisation.
Frequency:
Typically submitted every 6 months, annually, or at intervals defined by the product’s risk profile or regulatory authority requirements.
Key Contents:
- Executive Summary
- Worldwide marketing authorisation status
- Update on actions taken for safety reasons
- Estimated patient exposure
- Individual Case Safety Reports (ICSRs) summary
- Benefit-risk evaluation and conclusions
UK Focus:
MHRA requires PBRER submissions for centrally and nationally authorised products in line with international standards (ICH E2C(R2)).
2. DSUR (Development Safety Update Report)
What It Is:
DSUR is required for investigational medicinal products during clinical development. It harmonizes the reporting requirements during trials.
Frequency:
Submitted annually throughout the clinical development period.
Key Contents:
- Introduction and product development status
- Cumulative safety data (both pre-clinical and clinical)
- Important risks identified in trials
- Safety actions taken
- Benefit-risk considerations for ongoing development
UK Focus:
The MHRA mandates DSUR submission as part of clinical trial safety oversight for UK-based studies, aligned with ICH E2F guidelines.
3. PSUR (Periodic Safety Update Report)
What It Is:
PSUR is the precursor to PBRER, used mainly in regions where the transition to PBRER is still in progress. In practice, the PBRER has mostly replaced PSUR in the EU and UK.
Frequency:
Usually submitted every 6 months to 5 years, based on the product’s age and risk level.
Key Contents:
- Summary of product safety
- New information since the last report
- ICSR summary
- Safety profile update
- Regulatory actions and changes
UK Focus:
Legacy products or specific regional regulations might still require a PSUR format, but newer products typically use the PBRER structure.
4. PADER (Periodic Adverse Drug Experience Report)
What It Is:
PADER is a US FDA requirement, but many global companies prepare this alongside other aggregate reports to maintain consistency. It summarizes adverse events from the US market.
Frequency:
Submitted quarterly for the first 3 years post-approval, then annually.
Key Contents:
- Narrative summaries of serious, unexpected adverse experiences
- Analysis of 15-day alert reports
- Labeling changes
- Cumulative adverse experience data
UK Consideration:
While not required by the MHRA, companies with global operations often align PADER preparation timelines with other reporting schedules for consistency.
Comparison Summary
| Report | Lifecycle Stage | Regulatory Region | Frequency | Main Focus |
|---|---|---|---|---|
| PBRER | Post-marketing | UK/EU/Global | 6–12 months | Benefit-Risk Evaluation |
| DSUR | Clinical Trials | UK/EU/Global | Annually | Safety in Development |
| PSUR | Post-marketing | Legacy products | Varies | Safety Profile Summary |
| PADER | Post-marketing | USA | Quarterly/Annually | Adverse Event Summary |
Navigating aggregate safety reports is critical for regulatory compliance and proactive pharmacovigilance. Understanding the purpose, structure, and submission requirements for each report—PBRER, DSUR, PSUR, and PADER—helps pharmaceutical companies maintain regulatory alignment and safeguard public health.
How Q&V Can Help
At Quality & Vigilance (Q&V), we specialize in end-to-end pharmacovigilance solutions. From writing and compiling aggregate reports to ensuring timely submissions and regulatory compliance, our experts can support you at every stage.
Contact us today to streamline your aggregate reporting processes and stay inspection-ready.